A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.
David S. Hong
Research Funding - ISIS
Anas Younes
Consultant or Advisory Role - ISIS
Luis Fayad
No relevant relationships to disclose
Nathan Hale Fowler
No relevant relationships to disclose
Fredrick B. Hagemeister
No relevant relationships to disclose
Reena Mistry
Research Funding - ISIS
John J. Nemunaitis
Research Funding - ISIS
Mitesh J. Borad
Research Funding - ISIS
Alan H. Bryce
Consultant or Advisory Role - ISIS
Mason Yamashita
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Steven George Hughes
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Theodore Jesse Kwoh
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
A. Robert MacLeod
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Dan Norris
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Ron Baldwin
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Gene Hung
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Brett P. Monia
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Razelle Kurzrock
Research Funding - ISIS